T-CD20 kinetics in patients switching to ocrelizumab therapy from fingolimod versus dimethylfumarate

被引：0
|
作者：
Signoriello, Elisabetta [1 ]
Romano, Giuseppe [1 ]
Abbondanza, Ciro [2 ]
D'agostino, Marina [2 ]
Maglio, Grazia [2 ]
Miele, Giuseppina [1 ]
Missione, Rosanna [1 ]
Coppola, Cinzia [1 ]
Bonavita, Simona [1 ]
Lus, Giacomo [1 ]
机构：
[1] Univ Campania Luigi Vanvitelli, Div Neurol 2, Dept Surg & Med Sci Neurol Metab & Aging, Multiple Sclerosis Ctr, Naples, Italy
[2] Univ Campania Luigi Vanvitelli, Dipartimento Med Precis, Naples, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1530/1116
引用
收藏
页码：975 / 975
页数：1
相关论文
共 50 条
  • [1] Increased relapses in patients switching from natalizumab to dimethylfumarate, fingolimod and teriflunomide
    Vu, N.
    Moses, H.
    Sriram, S.
    Pawate, S.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 574 - 574
  • [2] Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients
    Gingele, Stefan
    Jacobus, Thais Langer
    Konen, Franz Felix
    Huemmert, Martin W.
    Suehs, Kurt-Wolfram
    Schwenkenbecher, Philipp
    Ahlbrecht, Jonas
    Moehn, Nora
    Mueschen, Lars H.
    Boenig, Lena
    Alvermann, Sascha
    Schmidt, Reinhold E.
    Stangel, Martin
    Jacobs, Roland
    Skripuletz, Thomas
    CELLS, 2019, 8 (01)
  • [3] BMI influences CD20 kinetics in multiple sclerosis patients treated with ocrelizumab
    Signoriello, E.
    Bonavita, S.
    Di Pietro, A.
    Abbadessa, G.
    Rossi, F.
    Miele, G.
    Casertano, S.
    Lus, G.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 43
  • [4] COST UTILITY ANALYSIS OF OCRELIZUMAB VERSUS FINGOLIMOD IN RELAPSING REMITTING MULTIPLE SCLEROSIS PATIENTS IN EGYPT FROM PAYOR PERSPECTIVE
    Ibrahim, A.
    Anan, I
    VALUE IN HEALTH, 2022, 25 (12) : S137 - S137
  • [5] Characterization of cytokine profiles in patients with multiple sclerosis under anti-CD20 therapy with ocrelizumab
    Koerner, Gudrun
    Gingele, Stefan
    Christina, Anna
    Pietschmann, Saparilla
    Konen, Franz Felix
    Jendretzky, Konstantin Fritz
    Schwenkenbecher, Philipp
    Hummert, Martin W.
    Jacobs, Roland
    Skripuletz, Thomas
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 231 - 232
  • [6] Characteristics of Patients Switching from Anti-CD20 Therapy to Natalizumab in the Treatment of Multiple Sclerosis
    Vollmer, Brandi
    Nair, Kavita
    Corboy, John
    Vollmer, Timothy
    Alvarez, Enrique
    NEUROLOGY, 2019, 92 (15)
  • [7] Switching MS patients from natalizumab to fingolimod therapy: comparison of short and prolonged washout periods
    Raciborska, D.
    Turner, B.
    Schmierer, K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 350 - 350
  • [8] Evaluation of T and B lymphocytopenia in patients treated with ocrelizumab switching from other treatments compared to naive
    Landi, D.
    Grimaldi, A.
    Bovis, F.
    Signoriello, E.
    Nicoletti, C. G.
    Cola, G.
    Lus, G.
    Sormani, M. P.
    Marfia, G. A.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 4 - 5
  • [9] A short washout period from fingolimod to anti-CD20 therapy is safe and decreases the risk of reactivation
    Gassama, S.
    Garmendia, A.
    Lejeune, F. X.
    de la Motte, M. Boudot
    Louapre, C.
    Papeix, C.
    Maillart, E.
    Roux, T.
    REVUE NEUROLOGIQUE, 2023, 179 (09) : 1035 - 1038
  • [10] Brain MRI Activity and Atrophy Measures in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the Open-Label Extension Period of the Phase III Trials of Ocrelizumab in Patients With Relapsing Multiple Sclerosis
    Arnold, Douglas
    Kappos, Ludwig
    Hauser, Stephen
    Montalban, Xavier
    Traboulsee, Anthony
    Wolinsky, Jerry
    Levesque, Victoria
    Villoslada, Pablo
    Belachew, Shibeshih
    Model, Fabian
    Hubeaux, Stanislas
    Bar-Or, Amit
    NEUROLOGY, 2018, 90
12345